Training Example: RINVOQ (AbbVie Inc.) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

RINVOQ (AbbVie Inc.)

(https://rinvoq.com) 📸 Data Snapshot: June 19, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA & JPsA (https://rinvoq.com)
Title

RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA & JPsA

Meta

Learn about RINVOQ® (upadacitinib), a once-daily pill that helps tame symptoms in eight conditions. See full Prescribing & Safety Info, and BOXED WARNING.

H1 See how RINVOQ helps tame symptoms in 9 conditions
H2 You could pay $0 a month§ for RINVOQ
H2 About RINVOQ
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Terms and Conditions
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 You are now leaving the RINVOQ website
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 US Healthcare Professionals Only
H3 USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 USES
H5 RINVOQ (upadacitinib)
H5 Important Information for Patients
H5 Information from AbbVie
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER RINVOQ® (upadacitinib) for Polyarticular JIA (pJIA) & Juvenile PsA (JPsA) (https://rinvoq.com/pjia-jpsa/)
Title

RINVOQ® (upadacitinib) for Polyarticular JIA (pJIA) & Juvenile PsA (JPsA)

Meta

Ask your child’s rheumatologist about RINVOQ® for Polyarticular Juvenile Idiopathic Arthritis (pJIA) or Juvenile Psoriatic Arthritis (JPsA). See Full Safety & Prescribing Info.

H1 NOT AN INJECTION Taken as a liquid or a pill
H2 RINVOQ LQ twice-daily oral solution
H2 RINVOQ once-daily pill
H2 You could pay $0 a month* for RINVOQ
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Terms and Conditions
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 You are now leaving the RINVOQ website
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 US Healthcare Professionals Only
H3 USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 USES
H5 RINVOQ (upadacitinib)
H5 Important Information for Patients
H5 Information from AbbVie
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER RINVOQ® (upadacitinib) Cost (https://rinvoq.com/cost/)
Title

RINVOQ® (upadacitinib) Cost

Meta

Find the cost for RINVOQ based on your health insurance or other financial options. See full Prescribing & Safety Information and BOXED WARNING.

H1 Cost & Savings
H2 RINVOQ® (upadacitinib) Cost
H2 Insurance Information*
H2 Insurance Coverage Support
H2 With RINVOQ Complete Savings Card, you could pay $0 a month*
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Terms and Conditions
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 You are now leaving the RINVOQ website
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 US Healthcare Professionals Only
H3 On this page
H3 USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 USES
H4 If you have…
H4 You could pay…
H4 *Important details about understanding your individual costs:
H5 RINVOQ (upadacitinib)
H5 Important Information for Patients
H5 Information from AbbVie
NAV_HEADER_REPEATED Sign Up for More Information | RINVOQ® (upadacitinib) (https://rinvoq.com/sign-up/)
Title

Sign Up for More Information | RINVOQ® (upadacitinib)

Meta

Sign up for information and support for people taking or considering RINVOQ (upadacitinib). See Full Prescribing & Safety Info, and BOXED WARNING.

H1 Sign Up
H2 You are now leaving the RINVOQ website
H2 Terms and Conditions
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 Terms and Conditions
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 You are now leaving the RINVOQ website
H2 Leaving AbbVie Web Site
H2 US Healthcare Professionals Only
H2 US Healthcare Professionals Only
H3 USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 IMPORTANT SAFETY INFORMATION & USES
H3 USES
H5 RINVOQ (upadacitinib)
H5 Important Information for Patients
H5 Information from AbbVie
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://rinvoq.com) RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA & JPsA
Learn how AbbVie could help you save. 1-800-2RINVOQ

Choose Your Condition

Moderate to SevereEczema(Atopic Dermatitis)*

Moderate to SevereRheumatoid Arthritis†

ActivePsoriatic Arthritis†

ActiveAnkylosing Spondylitis†

ActiveNr-axSpA† (Non-radiographic Axial Spondyloarthritis)

Moderate to SevereUlcerative Colitis‡

Moderate to SevereCrohn’s Disease‡

Giant Cell Arteritis

NOW APPROVEDActiveJuvenile Psoriatic Arthritis

[IMG: RINVOQ upadacitinib RINVOQ LQ upadacitinib 1mg/mL oral solution]

RINVOQ/RINVOQ LQ is approved in children 2+ years with active pJIA and in children 2 to less than 18 years with active psoriatic arthritis when TNF blockers did not work well or could not be tolerated. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your healthcare provider.

Active PolyarticularJuvenile Idiopathic Arthritis†

ActiveJuvenile Psoriatic Arthritis†

*Not well controlled with other pills or injections, including biologics.
†When TNF blockers did not work well or could not be tolerated.
‡When a TNF blocker did not work well or could not be tolerated, or after a different injection or pill when TNF blockers are not recommended by your healthcare provider.

[IMG: RINVOQ Complete]

[H2] You could pay $0 a month§ for RINVOQ

With the RINVOQ Complete Savings Card, you may pay as little as $0 a month for your prescription if you are an eligible, commercially insured patient. Offering more than just savings, RINVOQ Complete gives you support—on your terms. Whether you need a hand navigating your insurance or have a question about your condition, RINVOQ Complete is there to help you start and stay on track with your prescribed RINVOQ treatment plan.

Discover ways to save and more

§For eligible, commercially insured patients. Please see Terms and Conditions here.

See full Important Safety Information and Uses below

[H2] About RINVOQ

RINVOQ is a Janus kinase (JAK) inhibitor that works inside your cells to block certain signals that are thought to cause inflammation.
RINVOQ, a once-daily pill, has been shown to help tame symptoms in 9 conditions.

Your story can help others
Have you or a loved one been prescribed RINVOQ? Share your experience to help inform and inspire people like yourself. To participate:
email us at info@SPEAKnetwork.net or
call 855-465-8585

§Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

[H3] USES
RINVOQ is a prescription medicine used to treat:
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.
Adults with giant cell arteritis (GCA).
Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.
RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)
What is the most important information I should know about RINVOQ**?
RINVOQ may cause serious side effects, including:
Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster).
Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor.
Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen.
Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker.
Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor.
Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.
Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting.
Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as:
-Fever, sweating, or chills
-Shortness of breath
-Warm, red, or painful skin or sores on your body
-Muscle aches
-Feeling tired
-Blood in phlegm
-Diarrhea or stomach pain
-Cough
-Weight loss
-Burning when urinating or urinating more often than normal
Have TB or have been in close contact with someone with TB.
Are a current or past smoker.
Have had a heart attack, other heart problems, or stroke.
Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.
Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.
Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP.
Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.
Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose.
There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110.
Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
Medicines for fungal or bacterial infections
Rifampicin or phenytoin
Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.
Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including:
-Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back
-Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
-Pain or discomfort in your arms, back, neck, jaw, or stomach
-Shortness of breath with or without chest discomfort
-Breaking out in a cold sweat
-Nausea or vomiting
-Feeling lightheaded
-Weakness in one part or on one side of your body
-Slurred speech
Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including:
-Swelling
-Pain or tenderness in one or both legs
-Sudden unexplained chest or upper back pain
-Shortness of breath or difficulty breathing
Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, swelling of the feet and hands (peripheral edema), increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your HCP.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ/RINVOQ LQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in
15000 chars
SUB-PAGE (https://rinvoq.com/pjia-jpsa/) RINVOQ® (upadacitinib) for Polyarticular JIA (pJIA) & Juvenile PsA (JPsA)
Learn how AbbVie could help you save. 1-800-2RINVOQ

RINVOQ/RINVOQ LQ IS

[IMG: Approved]

for pJIA & JPsA† in ages 2+

Ask your child’s rheumatologist how RINVOQ can help them stand up to polyarticular juvenile idiopathic arthritis (pJIA) or juvenile psoriatic arthritis (JPsA).

†JPsA = juvenile psoriatic arthritis in children 2 to less than 18 years

Not an actual patient

For children 2+ years with active polyarticular juvenile idiopathic arthritis in whom TNF blockers did not work well.
For children 2 to less than 18 years of age with active psoriatic arthritis in whom TNF blockers did not work well.

For children 2+ years with active polyarticular course juvenile idiopathic arthritis in whom TNF blockers did not work well.
For children 2+ years with active juvenile psoriatic arthritis.

[H1] NOT AN INJECTION
Taken as a liquid or a pill

RINVOQ is available as RINVOQ LQ oral solution (a twice-daily liquid), or RINVOQ tablets (a once-daily pill). The exact dosing is based on your child's weight. Your child should always take RINVOQ exactly as prescribed by their doctor. Refer to the Instructions for Use on how to prepare and give a dose of RINVOQ LQ oral solution.
RINVOQ LQ oral solution is not interchangeable or substitutable with RINVOQ tablets.

[IMG: First and only oral JAK for pJIA and JPsA approved for ages 2+]

[H2] RINVOQ LQ twice-daily oral solution

Children weighing at least 22 pounds (10 kg) may be prescribed RINVOQ LQ oral solution.

Give RINVOQ LQ oral solution twice daily, with or without food
Avoid food or drink containing grapefruit

Do not dilute or mix the oral solution

[H2] RINVOQ once-daily pill

Children weighing greater than 66 pounds (30 kg) may be prescribed either RINVOQ LQ oral solution or RINVOQ tablets.

Give a RINVOQ pill once daily, with or without food
Avoid food or drink containing grapefruit

Do not split, crush, or chew the pill

Call your child's healthcare provider if you see medication residue (a whole tablet or tablet pieces) in their stool.

[IMG: Pill not actual size]

[H2] You could pay $0 a month* for RINVOQ

The RINVOQ Complete Savings Card may help eligible commercially insured patients pay as little as $0 a month for RINVOQ.

See how you can save

Not an actual patient

*Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

[H3] USES

RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
• Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
• Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)
What is the most important information I should know about RINVOQ**?
RINVOQ may cause serious side effects, including:
Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster).
Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor.
Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen.
Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker.
Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor.
Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.
Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting.
Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as:
-Fever, sweating, or chills
-Shortness of breath
-Warm, red, or painful skin or sores on your body
-Muscle aches
-Feeling tired
-Blood in phlegm
-Diarrhea or stomach pain
-Cough
-Weight loss
-Burning when urinating or urinating more often than normal
Have TB or have been in close contact with someone with TB.
Are a current or past smoker.
Have had a heart attack, other heart problems, or stroke.
Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.
Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.
Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP.
Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.
Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose.
There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110.
Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
Medicines for fungal or bacterial infections
Rifampicin or phenytoin
Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.
Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including:
-Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back
-Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
-Pain or discomfort in your arms, back, neck, jaw, or stomach
-Shortness of breath with or without chest discomfort
-Breaking out in a cold sweat
-Nausea or vomiting
-Feeling lightheaded
-Weakness in one part or on one side of your body
-Slurred speech
Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including:
-Swelling
-Pain or tenderness in one or both legs
-Sudden unexplained chest or upper back pain
-Shortness of breath or difficulty breathing
Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, swelling of the feet and hands (peripheral edema), increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your HCP.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ/RINVOQ LQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your HCP.
**Unless otherwise stated, "RINVOQ" in the IMPORTANT SAFETY INFORMATION refers to RINVOQ and RINVOQ LQ.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.
Adults with giant cell arteritis (GCA).
Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
15000 chars
SUB-PAGE (https://rinvoq.com/cost/) RINVOQ® (upadacitinib) Cost
Learn how AbbVie could help you save. 1-800-2RINVOQ

[H1] Cost & Savings

The amount you pay for RINVOQ can depend on a number of factors, including your access to prescription drug coverage, the type of insurance you have, and even the level of coverage your insurance may provide.
This page provides information that can help you determine how much RINVOQ may cost for you, as well as financial support programs that may be able to help you afford your medication.

[H3] On this page

RINVOQ
List Price >

Insurance
Information >

Insurance Coverage
Support >

Savings
Program >

RINVOQ List Price >

Insurance Information >

Insurance Coverage Support >

Savings Program >

myAbbVie Assist >

[H2] RINVOQ® (upadacitinib) Cost

The list price, also known as the Wholesale Acquisition Cost (WAC), for a 30-day supply of RINVOQ, is $7,090.41 as of January 6, 2026. The WAC may not reflect the price paid by patients.
Call 1-800-2RINVOQ (1-800-274-6867) to find out how much RINVOQ will cost for you.

[H2] Insurance Information*

[H4] If you have…

[H4] You could pay…

Commercial Insurance (usually provided by an employer)

$0 a month with the RINVOQ Complete Savings Card.†
Learn about the card

Medicaid

$8.00 or less per month, depending on state plan

Medicare Part D

$0-$2,100‡, depending on coverage phase
‡Represents catastrophic phase RINVOQ cost.
Out-of-pocket cost for RINVOQ may vary depending on patient's other medication costs.
Most Medicare patients have standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1-800-2RINVOQ
(1-800-274-6867)
As of January 1st, 2026, Medicare Part D benefits have changed to help patients better afford their medication: 
 Everyone with Medicare Part D prescription drug coverage will pay no more than $2,100 per year in covered out-of-pocket (OOP) costs. This includes the cost of the deductible. You will automatically receive this benefit once you are enrolled in a Part D plan. 
 You’ll have the option to pay your out-of-pocket drug costs in the form of monthly payments instead of all at once by signing up for the Medicare Prescription Payment Plan (MPPP) through your Part D plan. To sign up for the MPPP, you must contact your Medicare Part D plan. They will help you complete the MPPP application process. 
Visit www.medicare.gov to learn more about the new Medicare Prescription Payment Plan.

Medicare Low Income Subsidy (LIS)

$12.65 or less per dose starting January 1, 2026

Other Insurance (VA, DOD, TRICARE, Others)

Because coverage varies by plan, call 1-800-2RINVOQ
(1-800-274-6867) to speak to an Insurance Specialist to find out how much RINVOQ will cost for you.

Uninsured or if you cannot afford your medication

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit
AbbVie.com/PatientAccessSupport to learn more.

[H4] *Important details about understanding your individual costs:

The chart above provides cost information based on what a person with the type of coverage listed may pay for. Your type of health or prescription insurance plan will determine exactly how much you will pay. Information listed is accurate as of January 14, 2026 and is based on publicly available benefit design information for Medicaid and Medicare Part D out-of-pocket costs for 2026 plan year.

[H2] Insurance Coverage Support

To help you understand your coverage and what your out-of-pocket costs may be, it’s important to verify your benefits.
And even if your RINVOQ isn’t covered, there may be ways to save on your prescription. An Insurance Specialist can talk you through your coverage and help identify potential savings options — regardless of your insurance coverage.

For insurance questions or to verify your benefits, call 1-800-2RINVOQ (1-800-274-6867)

[H2] With RINVOQ Complete Savings Card, you could pay $0 a month*

The RINVOQ Complete Savings Card can make prescription cost as little as $0 a month for eligible patients with commercial insurance.
Find out how you can start saving today!

Learn more

*For eligible, commercially insured patients. Please see Terms and Conditions here.

[IMG: RINVOQ® complete savings card.]

[H3] USES
RINVOQ is a prescription medicine used to treat:
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.
Adults with giant cell arteritis (GCA).
Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.
RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)
What is the most important information I should know about RINVOQ**?
RINVOQ may cause serious side effects, including:
Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster).
Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor.
Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen.
Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker.
Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor.
Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.
Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting.
Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as:
-Fever, sweating, or chills
-Shortness of breath
-Warm, red, or painful skin or sores on your body
-Muscle aches
-Feeling tired
-Blood in phlegm
-Diarrhea or stomach pain
-Cough
-Weight loss
-Burning when urinating or urinating more often than normal
Have TB or have been in close contact with someone with TB.
Are a current or past smoker.
Have had a heart attack, other heart problems, or stroke.
Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.
Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.
Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP.
Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.
Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose.
There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110.
Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
Medicines for fungal or bacterial infections
Rifampicin or phenytoin
Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.
Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including:
-Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back
-Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
-Pain or discomfort in your arms, back, neck, jaw, or stomach
-Shortness of breath with or without chest discomfort
-Breaking out in a cold sweat
-Nausea or vomiting
-Feeling lightheaded
-Weakness in one part or on one side of your body
-Slurred speech
Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including:
-Swelling
-Pain or tenderness in one or both legs
-Sudden unexplained chest or upper back pain
-Shortness of breath or difficulty breathing
Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common col
15000 chars
SUB-PAGE (https://rinvoq.com/sign-up/) Sign Up for More Information | RINVOQ® (upadacitinib)
Learn how AbbVie could help you save. 1-800-2RINVOQ

[H1] Sign Up

You’re only a few clicks away from getting the RINVOQ information and resources that can help you take your condition head on. Just tell us a little bit about yourself and we’ll help you get started.

[H3] USES
RINVOQ is a prescription medicine used to treat:
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.
Adults with giant cell arteritis (GCA).
Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.
RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)
What is the most important information I should know about RINVOQ**?
RINVOQ may cause serious side effects, including:
Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster).
Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor.
Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen.
Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker.
Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor.
Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.
Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting.
Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as:
-Fever, sweating, or chills
-Shortness of breath
-Warm, red, or painful skin or sores on your body
-Muscle aches
-Feeling tired
-Blood in phlegm
-Diarrhea or stomach pain
-Cough
-Weight loss
-Burning when urinating or urinating more often than normal
Have TB or have been in close contact with someone with TB.
Are a current or past smoker.
Have had a heart attack, other heart problems, or stroke.
Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.
Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.
Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP.
Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.
Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose.
There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110.
Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
Medicines for fungal or bacterial infections
Rifampicin or phenytoin
Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.
Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including:
-Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back
-Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
-Pain or discomfort in your arms, back, neck, jaw, or stomach
-Shortness of breath with or without chest discomfort
-Breaking out in a cold sweat
-Nausea or vomiting
-Feeling lightheaded
-Weakness in one part or on one side of your body
-Slurred speech
Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including:
-Swelling
-Pain or tenderness in one or both legs
-Sudden unexplained chest or upper back pain
-Shortness of breath or difficulty breathing
Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, swelling of the feet and hands (peripheral edema), increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your HCP.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ/RINVOQ LQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your HCP.
**Unless otherwise stated, "RINVOQ" in the IMPORTANT SAFETY INFORMATION refers to RINVOQ and RINVOQ LQ.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.
Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated.
Adults with giant cell arteritis (GCA).
Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.
It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.
RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.
It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
If you are having difficulty paying for your medicine, Ab
15000 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
3Review mentions (all pages)
5External proof links (all pages)
PageReviewsProof links
/ (home) 1 1
/pjia-jpsa/ 0 1
/cost/ 1 1
/sign-up/ 1 2
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Rheumatology",
    "reviewedBy": "AbbVie Inc.",
    "dateModified": "2022-10-21",
    "headline": "RINVOQ® (upadacitinib) Treatment for RA, PsA, AD, AS, nr-axSpA and UC",
    "description": "Learn about RINVOQ® (upadacitinib), a once-daily pill that helps tame symptoms in six conditions. See full Prescribing & Safety Info, and BOXED WARNING.",
    "url": "https://www.rinvoq.com/",
    "primaryImageOfPage": [
        {
            "@type": "ImageObject",
            "name": "Rinvoq Relief is Possible: RINVOQ is a once-daily pill that helps tame symptoms in 6 conditions",
            "url": "https://www.rinvoq.com/content/dam/rinvoq/images/homepage/rinvoq-relief-is-here_1200-1800.png"
        }
    ],
    "potentialaction": {
        "0": {
            "@type": "ViewAction",
            "name": "Eczema",
            "url": "https://www.rinvoq.com/atopic-dermatitis"
        },
        "1": {
            "@type": "ViewAction",
            "name": "Rheumatoid Arthritis",
            "url": "https://www.rinvoq.com/rheumatoid-arthritis"
        },
        "2": {
            "@type": "ViewAction",
            "name": "Psoriatic Arthritis",
            "url": "https://www.rinvoq.com/psoriatic-arthritis"
        },
        "3": {
            "@type": "ViewAction",
            "name": "Ankylosing Spondylitis",
            "url": "https://www.rinvoq.com/ankylosing-spondylitis"
        },
        "4": {
            "@type": "ViewAction",
            "name": "Non-radiographic Axial Spondyloarthritis",
            "url": "https://www.rinvoq.com/non-radiographic-axial-spondyloarthritis"
        },
        "_items_truncated": true
    },
    "image": [
        {
            "@type": "ImageObject",
            "name": "RINVOQ® Complete logo",
            "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/homepage/rinvoq-complete-logo-white-brushstroke-desktop-r9.png"
        }
    ],
    "mainEntity": [
        {
            "@type": "Question",
            "text": "What is the most important information I should know about RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "RINVOQ may cause serious side effects, including: Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You "
                ]
            }
        },
        {
            "@type": "Question",
            "text": "What should I tell my HCP before taking RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "Tell your HCP if you: Are being treated for an infection, have an infection that won’t go away or keeps coming back, or have symptoms of an infection, such as: - Fever, sweating, or chills - Shortness of breath - Warm, red, or painful skin or sores on your body - Muscle aches - Feeling tired - Blood in phlegm - Diarrhea or stomach pain - Cough - Weight loss - Burning when urinating or urinating more often than normal. Have TB or have been in close contact with someone with TB. Are a current or p"
                ]
            }
        },
        {
            "@type": "Question",
            "text": "What should I tell my HCP after starting RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: - Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back - Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw - Pain or discomfort in your ar"
                ]
            }
        },
        {
            "@type": "Question",
            "text": "What are the common side effects of RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "These include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections, including cold sores, bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, low white blood cell count (neutropenia), muscle pain, and flu-like illness. A separation or tear to the lining of the b"
                ]
            }
        },
        {
            "@type": "Question",
            "text": "How should I take RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg and 30 mg extended-release tablets."
                ]
            }
        }
    ],
    "about": [
        {
            "@type": "Drug",
            "name": "RINVOQ",
            "nonProprietaryName": "upadacitinib",
            "image": {
                "@type": "ImageObject",
                "name": "Rinvoq (upadacitinib) Logo",
                "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/common/rinvoq-logo-white-desktop-r9.png"
            },
            "description": "RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. ",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf",
            "warning": "Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ. If a serious infection develops, interrupt RINVOQ until the infection is controlled. Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ. Monitor all patients for active tuberculosis during treatment, even if th",
            "pregnancyWarning": "The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or  iscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. ",
            "breastfeedingWarning": "There are no data on the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with upadacit",
            "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
            "dosageForm": [
                "Tablet"
            ],
            "administrationRoute": "oral",
            "doseSchedule": {
                "@type": "DoseSchedule",
                "frequency": "daily",
                "doseValue": "15",
                "doseUnit": "mg"
            },
            "manufacturer": {
                "@type": "Corporation",
                "name": "Abbvie"
            }
        }
    ],
    "_truncated": true,
    "_original_size": 11731
}
/pjia-jpsa/ — no schema detected (entity gap)
/cost/
{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Rheumatology",
    "reviewedBy": "AbbVie Inc.",
    "dateModified": "2022-04-12",
    "headline": "RINVOQ® (upadacitinib) Cost",
    "description": "Find the cost for RINVOQ based on your health insurance or other financial options. See full Prescribing & Safety Information and BOXED WARNING.",
    "url": "https://www.rinvoq.com/cost",
    "primaryImageOfPage": [
        {
            "@type": "ImageObject",
            "name": "With RINVOQ Complete Savings Card, you could pay $5 a month",
            "url": "https://www.rinvoq.com/content/dam/rinvoq/images/homepage/temp-cost-and-savings/savings-card_r13_desktop.png"
        }
    ],
    "potentialaction": [
        {
            "@type": "ViewAction",
            "name": "Learn about the card",
            "description": "You could pay $5 a month with the RINVOQ Complete Savings Card",
            "url": "https://www.rinvoq.com/resources/save-on-rinvoq-costs"
        },
        {
            "@type": "ViewAction",
            "name": "Uninsured or if you cannot afford your medication",
            "description": "If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.",
            "url": "https://www.abbvie.com/patients/patient-assistance.html?utm_source=myAbbVie-Assist-URL"
        },
        {
            "@type": "ViewAction",
            "name": "myAbbVie Assist",
            "url": "https://www.abbvie.com/patients/patient-assistance.html?utm_source=myAbbVie-Assist-URL"
        }
    ],
    "about": [
        {
            "@type": "Drug",
            "name": "RINVOQ",
            "nonProprietaryName": "upadacitinib",
            "image": {
                "@type": "ImageObject",
                "name": "Rinvoq (upadacitinib) Logo",
                "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/common/rinvoq-logo-white-desktop-r9.png"
            },
            "description": "RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. ",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf",
            "warning": "Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ. If a serious infection develops, interrupt RINVOQ until the infection is controlled. Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with RINVOQ. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions.",
            "pregnancyWarning": "The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or  iscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. ",
            "breastfeedingWarning": "There are no data on the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with upadacitinib, and for 6 days (approximately 10 half-lives) after the last dose. ",
            "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
            "dosageForm": [
                "Tablet"
            ],
            "administrationRoute": "oral",
            "doseSchedule": {
                "@type": "DoseSchedule",
                "frequency": "daily",
                "doseValue": "15",
                "doseUnit": "mg"
            },
            "manufacturer": {
                "@type": "Corporation",
                "name": "Abbvie"
            }
        }
    ]
}
/sign-up/
{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Rheumatologic",
    "reviewedBy": "AbbVie Inc.",
    "dateModified": "2022-02-16",
    "headline": "Sign Up for More Information | RINVOQ® (upadacitinib)",
    "description": "Sign up for information, resources, and support for people who are taking, or considering, RINVOQ. See Important Safety Information, including BOXED WARNING.",
    "url": "https://www.rinvoq.com/sign-up",
    "about": [
        {
            "@type": "Drug",
            "name": "RINVOQ",
            "nonProprietaryName": "upadacitinib",
            "image": {
                "@type": "ImageObject",
                "name": "Rinvoq (upadacitinib) Logo",
                "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/common/rinvoq-logo-white-desktop-r9.png"
            },
            "description": "RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. ",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf",
            "warning": "Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ. If a serious infection develops, interrupt RINVOQ until the infection is controlled. Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with RINVOQ. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions.",
            "pregnancyWarning": "The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or  iscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. ",
            "breastfeedingWarning": "There are no data on the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with upadacitinib, and for 6 days (approximately 10 half-lives) after the last dose. ",
            "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
            "dosageForm": [
                "Tablet"
            ],
            "administrationRoute": "oral",
            "doseSchedule": {
                "@type": "DoseSchedule",
                "frequency": "daily",
                "doseValue": "15",
                "doseUnit": "mg"
            },
            "manufacturer": {
                "@type": "Corporation",
                "name": "Abbvie"
            }
        }
    ]
}

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: RINVOQ (AbbVie Inc.) (rinvoq.com)

https://rinvoq.com 📍 Industry: Medical Devices, Pharma & Biotech
11 BS / 100

This is a low-BS, highly regulated pharmaceutical site where legal necessity forces a high substance-to-signal ratio. The minimal fluff present is confined to consumer-facing metaphors, while the core architecture is a forensic database of clinical and financial specifications. It is a benchmark for accuracy in a high-stakes industry.

Info Density Power-words vs. Substance ratio.
8
27% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
0
0% BS
Commodity Fingerprint Detection of industry clichés/templates.
1
7% BS
Identity & Authority Expert verifiability & Schema depth.
0
0% BS

To further reduce the BS score, consolidate the massive, repeated ‘USES’ and ‘ISI’ blocks into a single global footer or a sticky navigation element to reduce repetitive character counts. Link the ‘Share your story’ call to action to actual peer-reviewed outcomes or ClinicalTrials.gov results to ground patient experiences in data. Replace vague metaphors like ‘tame symptoms’ in the H1 with more specific clinical endpoints, such as ‘reduce inflammation markers.’ Ensure all H3 tags like ‘On this page’ are converted to substantive descriptors to improve the technical heading hierarchy.

The content perfectly aligns with the Pharmaceutical and Biotech industry standards, specifically focusing on a prescription JAK inhibitor. All pages contain the requisite FDA-mandated safety disclosures, indication lists, and prescribing information links typical of a regulated therapeutic product.

“The score of 11 is primarily driven by the 'Information Density' pillar, specifically the high volume of verbatim content repetition across sub-pages and the use of marketing power words in primary headings. The 'Semantic Coherence' pillar contributed a minor 2 points due to some structural heading inconsistencies. All other trust and authority pillars scored 0 or 1, as the site provides nearly 100% verifiable evidence for its claims.”

Verified Analysis Date: June 19, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result